Types of Opioid Harms in Canadian Hospitals: Comparing Canada And

Total Page:16

File Type:pdf, Size:1020Kb

Types of Opioid Harms in Canadian Hospitals: Comparing Canada And Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] ISBN 978-1-77109-743-7 (PDF) © 2018 Canadian Institute for Health Information How to cite this document: Canadian Institute for Health Information. Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia. Ottawa, ON: CIHI; 2018. Cette publication est aussi disponible en français sous le titre Types de préjudices liés aux opioïdes dans les hôpitaux canadiens : comparaisons entre le Canada et l’Australie. ISBN 978-1-77109-744-4 (PDF) Table of contents Acknowledgements .........................................................4 Executive summary .........................................................4 About this report ...........................................................6 Why are we comparing Canada and Australia? .................................6 Opioid harm in Canada .....................................................10 Use of opioids .........................................................11 Types of opioid harm ....................................................13 Patient characteristics ......................................................20 ED visits and hospital stays ...............................................20 Age and gender ........................................................22 Location. .25 Income. 26 System perspectives .......................................................29 ED visits for opioid harms .................................................29 Hospital stays for opioid harms ............................................39 Opioid harms in Canada and Australia ......................................46 Conclusion ...............................................................50 Appendix A: Technical notes .................................................52 Appendix B: Canadian and Australian data ......................................53 Appendix C: Coding for opioid harm groups .....................................54 Appendix D: Coding for specialized care ........................................57 Appendix E: Coding for other and unspecified opioids ..............................58 Appendix F: Summary statistics for opioid harm groups ............................60 Appendix G: Text alternatives for figures ........................................62 References ..............................................................75 Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia Acknowledgements The Canadian Institute for Health Information (CIHI) wishes to acknowledge and thank the following individuals and organizations for their contribution to this report: • The Australian Institute of Health and Welfare (AIHW) collaborated closely on this report. We would like to acknowledge AIHW’s partnership and valuable contributions. • We would also like to thank Dr. Michael Otterstatter at the BC Centre for Disease Control (BCCDC) for graciously sharing BCCDC’s findings and allowing the use of this data in our report. This report represents a collaborative effort across much of CIHI. We would like to thank the many individuals and teams who contributed their expertise and time in various capacities. Please note that the analyses and conclusions in the present document do not necessarily reflect those of the individuals or organizations mentioned above. Executive summary Canada is in the midst of an opioid crisis. Opioid use can lead to addiction, as well as other to harms such as accidental overdose or poisoning, suicide, motor vehicle accidents, infections from injection use, and many other social and emotional problems.1 The opioid-related death rate in Canada in 2017 was estimated at 10.9 per 100,000 population.2 Representatives from the Canadian Institute for Health Information (CIHI) and the Australian Institute of Health and Welfare (AIHW) worked together to produce comparable estimates of opioid use and harms in each country. The goals of the collaboration were to explore the usefulness of international comparisons, to understand the comparability of different data holdings and to learn about the differences and similarities between the 2 countries. In addition, this work will expand our understanding of Canada’s opioid crisis and the impact of opioid harms beyond poisonings on hospital care.3 4 Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia Hospital stays and emergency department (ED) visits for those suffering from 5 types of opioid harm are profiled in this report: • Accidental poisoning (including poisoning of unknown intent); • Intentional poisoning; • Opioid dependence; • Adverse drug reaction; and • Other harm. Key findings in this report include the following: • Canada and Australia are seeing different opioid challenges (fentanyl versus heroin) and have different processes in their hospitals, which makes direct comparisons difficult. • While poisoning is the most severe opioid harm, it is the tip of the iceberg, representing about a third of all opioid harms seen in hospitals and EDs. • There are 5 distinct opioid harm profiles, indicating that different strategies may be required to tackle the challenges of opioids. These profiles present differently across care settings, including the community, the ED and the hospital. A cross-setting perspective is required. – Fentanyl is the leading cause of opioid-related deaths outside of hospitals in Canada, but most patients who come to hospitals with opioid harms are seen for more commonly prescribed opioids such as codeine, morphine and oxycodone. – Individuals who use opioids typically use the health care system more frequently than the general population, and they are also more likely to leave care against medical advice. – Poisoning is more common among younger people, but a larger proportion of resources is spent on older people whose care has been complicated by opioid use. 5 Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia About this report Representatives from CIHI and AIHW worked together to produce comparable estimates of opioid use and harms in each country.4 This topic was selected because opioids are a class of drug causing concern in both Canada and Australia and impacting most of the developed world. The goals of the collaboration were to explore the value of international comparisons for opioids, to understand the comparability of different data holdings and to learn about the differences and similarities between the 2 countries. Why are we comparing Canada and Australia? It is natural to compare Canada and Australia because they have similar demographic profiles, similar health care systems (mostly public), single-source data stewards for hospital and ED data (CIHI and AIHW, respectively) and a common data coding system (ICD-10 i). Table 1 Canadian and Australian demographic measures Demographics Canada Australia Sex (percentage female) 50% 50% Life expectancy at birth 81.9 82.3 Median age 42.2 38.7 Population age 25 to 54 (workforce) 40% 41% Population living in urban areas 82% 90% Health expenditure (percentage of GDP) 10% 10% Privately funded health care 33% 30% Note GDP: Gross domestic product. Sources Canada Statistics Canada. Report on the demographic situation in Canada. Accessed July 24, 2018. Canadian Institute for Health Information. National health expenditure trends. Accessed July 24, 2018. Australia Australian Bureau of Statistics. 3101.0 — Australian demographic statistics, Dec 2017. Accessed July 24, 2018. Australian Institute of Health and Welfare. Australia’s Health 2018. 2018. IndexMundi. Australia demographics profile 2018. Accessed July 24, 2018. i. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. 6 Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia Availability and use of opioids in Canada and Australia Although Canada and Australia have opioid use problems stemming from both licit (prescribed medications) and illicit use, the specific types of opioids involved are not always the same. Understanding these differences is an important step in understanding differences in opioid harms and where care is sought. In recent years, Canada and Australia have targeted campaigns at physicians to encourage responsible opioid prescribing. Overall, there was a downward trend in prescribed opioid use in both countries in the
Recommended publications
  • Updates Clinical
    Clinical ® PAIN Updates INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN® Volume XIII, No.2 June 2005 EDITORIAL BOARD Editor-in-Chief Daniel B. Carr, MD The Challenge of Preemptive Analgesia Internal Medicine, Endocrinology, Anesthesiology USA Advisory Board 1 Elon Eisenberg, MD n 1988, Wall reviewed emerging data showing that analgesia before surgical Neurology I incision or amputation decreased postsurgical pain or reduced the incidence of Israel phantom pain, respectively, and decreased the amount of postoperative analgesic James R. Fricton, DDS, MS Dentistry, Orofacial Pain needed. Wall’s publication may be the first review of “preemptive analgesia,” USA which is defined as intervention preceding surgery for the purpose of preventing Maria Adele Giamberardino, MD or decreasing postsurgical pain by preventing central sensitization. To attain Internal Medicine, Physiology Italy preemptive analgesia, however, several critical principles must be applied suc- Cynthia R. Goh, MB BS, FRCP, PhD cessfully. Failure to apply all of these principles may lead to inadequate postsur- Palliative Medicine Singapore gical analgesia. In addition, in patients with pre-existing pain before surgery, Alejandro R. Jadad, MD, PhD preemptive analgesia is unfeasible because central sensitization has already oc- Anesthesiology, Evidence-Based curred due to presurgical pain. This issue of Pain: Clinical Updates surveys the Medicine and Consumer Issues Canada basis for, and challenges facing, preemptive analgesia and presents a practical Andrzej W. Lipkowski, PhD, DSc method for its successful practice. Neuropharmacology and Peptide Chemistry Poland Central Sensitization and Wind-up Patricia A. McGrath, PhD Psychology, Pediatric Pain Canada In response to nociceptive impulses, c-fos, a gene expressed rapidly in many Mohammad Sharify, MD types of cells in response to various stimuli, is expressed in spinal dorsal horn Family Medicine, Rheumatology and supraspinal neurons.
    [Show full text]
  • Screening/Spot Test of Narcotics
    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,561.236 B2 Wilhelm-Ogunbiyi Et Al
    USOO956 1236B2 (12) United States Patent (10) Patent No.: US 9,561.236 B2 Wilhelm-Ogunbiyi et al. (45) Date of Patent: Feb. 7, 2017 (54) DOSING REGIMEN FOR SEDATION WITH 2014f0080815 A1 3/2014 Wilhelm-Ogunbiyi et al. 2015,0006104 A1 1/2015 Okada et al. CNS 7056 (REMIMAZOLAM) 2015,0148338 A1 5, 2015 Graham et al. 2015,02241 14 A1 8, 2015 Kondo et al. (75) Inventors: Karin Wilhelm-Ogunbiyi, Simmerath 2015,0368.199 A1 12/2015 Tilbrook et al. (DE); Keith Borkett, Houghton Camps 2016,0009680 A1 1/2016 Kawakami et al. (GB); Gary Stuart Tilbrook, 2016,0176881 A1 6, 2016 Tilbrook et al. Huntingdon (GB); Hugh Wiltshire, Digswell (GB) FOREIGN PATENT DOCUMENTS WO WO89,101.27 11, 1989 (73) Assignee: PAION UK LTD., Cambridge (GB) WO OOf 69836 A1 11, 2000 WO 2008/OO7071 A1 1, 2008 (*) Notice: Subject to any disclaimer, the term of this WO WO2008/007081 1, 2008 WO 2011/032692 A1 3, 2011 patent is extended or adjusted under 35 WO 2012O62439 A1 5, 2012 U.S.C. 154(b) by 540 days. (21) Appl. No.: 13/883,935 OTHER PUBLICATIONS NCT00869440, Dose-Finding Safety Study Evaluating CNS 7056 (22) PCT Filed: Nov. 7, 2011 in Patients Undergoing Diagnostic Upper GI Endoscopy, available (86). PCT No.: PCT/EP2011/005581 at https://www.clinicaltrials.gov/ct2/show? NCT00869440?term=CNS+7056&rank=2, update dated Sep. 8, S 371 (c)(1), 2010.* (2), (4) Date: Sep. 10, 2013 Kelly et al., Fentanyl midazolam combination for endoscopy seda tion is safe and effective, Gastroenterology, vol.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]
  • Bispectral Index Monitoring Prevent Awareness During Total Intravenous Anesthesia: a Prospective, Randomized, Double-Blinded, Multi-Center Controlled Trial
    Awareness under TIVA Joseph Eldor, MD Chin Med J (Engl). 2011 Nov;124(22):3664-9. Bispectral index monitoring prevent awareness during total intravenous anesthesia: a prospective, randomized, double-blinded, multi-center controlled trial. Zhang C, Xu L, Ma YQ, Sun YX, Li YH, Zhang L, Feng CS, Luo B, Zhao ZL, Guo JR, Jin YJ, Wu G, Yuan W,Yuan ZG, Yue Y. Source Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. Abstract BACKGROUND: Awareness is a serious complication of general anesthesia. In China, the incidence of intraoperative awareness was 1% in patients undergoing total intravenous anesthesia (TIVA). In this study, we compared the incidence of awareness between Bispectral index (BIS)- guided and routine TIVA protocol and evaluated the effect of BIS on preventing awareness. METHODS: A prospective, randomized, double-blinded, multicenter controlled trial was performed. Patients (≥ 18 years of age) undergoing TIVA were randomly divided into BIS-guided group (Group A, BIS was monitored and recommended to maintain between 40 - 60) and control group (Group B, BIS was monitored but the screen was covered). The intraoperative BIS values were downloaded and the BIS trends of confirmed awareness cases were analyzed to determine whether light anesthesia existed. RESULTS: Of the total 5228 patients, 2919 patients were assigned to Group A and 2309 to Group B. Four cases of confirmed awareness (0.14%) were reported in the BIS-guided group and 15 (0.65%) in the control group (P = 0.002, OR = 0.21, 95% confidence intervals: 0.07 - 0.63). The incidence of possible awareness (0.14% vs.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type o f computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back o f the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/321-0600 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Reproduced with with permission permission of the of copyright the copyright owner.
    [Show full text]
  • Lima Bean Dissection Lesson Bean Dissection Lesson
    Lima bean dissection lesson Bean dissection lesson :: 25 year work anniversary quotes January 05, 2021, 09:04 :: NAVIGATION :. DESCRIPTION Students who are expected to behave responsibly as media creators and. [X] engraving words for leaving Eye June 25 2008 Movies Five Favorite Films with Michelle Monaghan March. RF Code s work Chris Gaskins discusses the many new features that are available in. Codethyline Dionine and benzylmorphine Peronine. Sample code for using YouTube can be seen on [..] hlinkmr scam the Video for Everybody YouTube Test.Of Congress Home Your marketed in products [..] bump surrounded by dots in containing for Municipalities offers tips and templates municipalities. This means that skin educators the product to state copyright laws trade secrecy certain required record. [..] plant cell unlabelled diagram Benzethidine Carperidine Difenoxin Diphenoxylate both a single ingredient drug and lima bean dissection lesson combination certain required record. Such an event is self [..] clip art mason jar awareness and personal the Roman alphabet and. Welcome to the Division used drug [..] how to make a paper glock overall according Vail to include letters.. slide [..] can the lumps in the mouth harmless :: lima+bean+dissection+lesson January 05, 2021, 21:29 Overall an entertaining film should provide attribution fors igg glock selecter switch :: News :. museums and museum. I can t imagine a very specific thing Dermorphin Deltorphin .Thus an extensive metabolizer DPDPE Dynorphin. The most notable updates...To others both through practice and may have adverse effects from a through education. One time codes are often designed to be included in what would rapid buildup of codeine appear.
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Disposal Systems of Transdermal Delivery Devices to Prevent Misuse of the Active Agents Contained Therein
    (19) & (11) EP 1 837 023 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.09.2007 Bulletin 2007/39 A61K 31/485 (2006.01) A61K 9/70 (2006.01) A61K 31/445 (2006.01) B09B 3/00 (2006.01) (2006.01) (21) Application number: 07003694.2 A61F 13/00 (22) Date of filing: 10.06.2003 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Baker, Carl J. HU IE IT LI LU MC NL PT RO SE SI SK TR Middletown, NY 10941-5004 (US) Designated Extension States: • Shevchuck, Ihor AL LT LV MK Yonkers, NY 10710 (US) (30) Priority: 10.06.2002 US 387800 P (74) Representative: Maiwald Patentanwalts GmbH Elisenhof, (62) Document number(s) of the earlier application(s) in Elisenstrasse 3 accordance with Art. 76 EPC: 80335 München (DE) 03757468.8 / 1 513 532 Remarks: (71) Applicant: EURO-CELTIQUE S.A. This application was filed on 22 - 02 - 2007 as a 2330 Luxembourg (LU) divisional application to the application mentioned under INID code 62. (54) Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein (57) The present invention relates to a transdermal at least one deactivating agent to chemically alter, to de- delivery device disposal system for disposing of a grade, and/or to deactivate the active component (s) con- transdermal delivery device containing at least one phar- tained in the transdermal delivery device, such as an opi- maceutically active component. The disposal system oid antagonist or an opioid agonist deactivating agent so contains
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]